Parapneumonic effusions related to Streptococcus pneumoniae: serotype and disease severity trends
=================================================================================================

* Catherine Hyams
* David T Arnold
* Robyn Heath
* Zahin Amin-Chowdhury
* David Hettle
* Gabriella Ruffino
* Paul North
* Charli Grimes
* Norman K Fry
* Philip Williams
* Leon Danon
* O Martin Williams
* Shamez Ladhani
* Adam Finn
* Nick A Maskell

## ABSTRACT

**Rationale** *Streptococcus pneumoniae* epidemiology is changing in response to vaccination and some data suggest empyema incidence is increasing. However, differences exist between UK and USA studies. We describe trends in the clinical phenotype of adult pneumococcal pleural infection, including simple parapneumonic effusions (SPE) in the pneumococcal conjugate vaccination (PCV) era.

**Objectives** To determine whether there were differences in pneumococcal disease presentation and severity associated with pleural infection.

**Methods** A retrospective cohort study, all adults ≥16 years admitted to three large UK hospitals, 2006-2018 with pneumococcal disease. 2477 invasive pneumococcal cases were identified: 459 SPE and 100 pleural infection cases. Medical records were reviewed for each clinical episode. Serotype data were obtained from the UK Health Security Agency national reference laboratory.

**Results** Incidence increased over time, including non-PCV-serotype disease. PCV7-serotype disease declined following paediatric PCV7 introduction, but the effect of PCV13 was less apparent as disease caused by the additional six serotypes plateaued with serotypes 1 and 3 causing such parapneumonic effusions from 2011 onwards.

Patients with pleural infection had a median survival 468 days (95% CI 340-590) in, versus 286 days (95% CI 274-335) in those with SPE. Pleural infection associated with frank pus had lower 90-day mortality than pleural infection without pus (0% versus 29%, *P*<0.0001). 90-day mortality could be predicted by baseline increased RAPID (Renal, Age, Purulence, Infection source, and Dietary factors) score (HR15.01, 95% CI 1.24-40.06, *P*=0.049).

**Conclusions** Pneumococcal infection continues to cause severe disease despite the introduction of PCVs. The predominance of serotype 1 and 3 in this adult UK cohort is in keeping with previous studies in paediatric and non-UK studies. Rising non-PCV serotype disease and limited impact of PCV13 on cases caused by serotypes 1 and 3 offset the reductions in adult pneumococcal parapneumonic effusion disease burden observed following introduction of the childhood PCV7 programme.

Keywords
*   Streptococcus pneumoniae
*   Empyema
*   Pleural Effusion

## INTRODUCTION

*Streptococcus pneumoniae* remains the leading bacterial cause of community-acquired pneumonia (CAP), despite vaccine deployment. A dose of PneumoVax® (unconjugated 23-valent polysaccharide vaccine, PPV23) is offered to all adults from age 65 years in the UK and ≥2-year-olds with at least one clinical risk factor for pneumococcal disease also receive this vaccine (1). The 7-valent pneumococcal conjugate vaccine (PCV) (PCV7) was introduced into the UK childhood vaccination programme in 2006 on a 2 priming dose schedule with a booster following the first birthday (2+1) and subsequently replaced in April 2010 with a 13-valent PCV (PCV13). The schedule was modified to 1+1 in 2020. Several USA studies have shown that PCV introduction resulted in a significant reduction in both carriage and invasive pneumococcal disease (IPD) due to vaccine serotypes, especially in children (2, 3) although an increase in pneumococcal empyema cases in children has been reported (4) and the effect of paediatric PCV deployment on adult disease phenotype is debated (5). By 2016/17, UK surveillance demonstrated that PCV7 serotype disease in children had virtually disappeared, with significant reduction in PCV7 disease burden in adults. In contrast, while PCV13 serotype disease incidence has not disappeared across all age groups, but plateaued, with a remaining residual incidence of 7·97 per 100,000 across all age groups. There has also been an increase in disease attributable to non-PCV13 serotypes, especially in the elderly, which has reduced overall disease reduction resulting from vaccine introduction (6-8). Evidence from a large pneumococcal pneumonia patient cohort in Nottingham, UK suggests that, aside from age, residential care status and some comorbidities, there are relatively few differences between patients with disease caused by PCV13 and those with non-PCV13 serotype infections (9).

Approximately 15-20% hospitalised pneumococcal CAP cases are associated with a pleural effusion (10, 11) and 6% with empyema (10, 12). However, recent evidence suggests that incidence of pneumococcal empyema has increased following paediatric PCV deployment, especially in adults aged >65 years, possibly due to serotype 1 emergence (13). Thus, vaccine-driven serotype replacement may be leading to changes in pneumococcal disease phenotype and severity. This is a concern as morbidity and mortality associated with simple parapneumonic effusion (SPE) are higher than with uncomplicated pneumonia (14).

Here we present the largest cohort of patients with a single-organism pleural infection, encompassing SPE and pleural infection (complex parapneumonic effusion (CPE) or empyema) attributable to pneumococcus, in a single-centre observational study covering thirteen years during which PCVs were introduced into the UK paediatric vaccination programme. We sought to determine whether there were any differences in pneumococcal disease presentation and severity associated with pleural infection, given concerns surrounding changing pneumococcal serotype distribution.

## MATERIALS AND METHODS

### Study Subjects

Patients aged ≥16 years admitted to all three hospitals providing emergency care in Bristol and Bath (University Hospitals Bristol and Weston, North Bristol and The Royal United Hospital NHS Trusts) between January 2006 and December 2018, with a confirmed microbiological diagnosis of pneumococcal infection were eligible for this study. This study was approved by the Health Research Authority, UK (IRAS 265437).

### Study Design

A retrospective cohort study at three large NHS hospitals in the UK.

### Methods

Study-eligible cases were identified retrospectively by searching the Laboratory Information Management System (LIMS) database (Clinisys WinPath Enterprise). *S. pneumoniae* was confirmed on culture from sterile-site sampling at a central laboratory using standard microbiological techniques combined with API®-20 Strep (BioMérieux, UK) or MALDI-TOF (matrix-assisted laser desorption/ionisation/time of flight) mass spectrometry (Bruker, UK) (15). A positive pneumococcal urinary-antigen test (BinaxNOW®, Alere, UK) was also considered confirmative of pneumococcal infection. Any patient with pleural fluid which cultured a single-organism which was not pneumococcus was excluded from this cohort; although, multi-organism pleural infection including pneumococcus was included.

Confirmed cases were linked with the UK Health Security Agency (UKHSA) national reference laboratory to obtain serotype data (16) which were collected separately from clinical data to avoid any risk of bias in data collection. Pneumococcal serotypes were grouped by PCV (PCV7; PCV13-7 representing the additional 6 serotypes in PCV13; and PCV13) or as non-PCV (Supplementary Data 1).

Patients with pneumococcal infection and a pleural effusion on radiology were either classified as

1.  pleural infection; if pleural fluid was pus; bacterial culture positive pleural fluid; an effusion relating to a current pneumonia episode which necessitated definitive drainage (e.g. thoracic surgery); or, there was an exudative effusion with pH ≤7.2; or,

2.  SPE; an exudative effusion not classified as pleural infection in a patient with a clinical and/or radiological diagnosis of pneumonia.

Patients’ clinical records were reviewed at each hospital and data, including clinical outcomes, recorded. The vaccination status of each patient was established from electronically linked GP records (15). The CURB65 severity score on admission was calculated for each clinical episode (17). Patients with pleural infection had a RAPID (Renal, Age, Purulence, Infection source, and Dietary factors) score calculated (18), which has been validated to stratify adults with pleural infection according to increasing risk of mortality (19).

### Analysis

Patient data are reported as medians and interquartile ranges (IQR) for continuous variables. Categorical variables are presented as counts and percentages. Baseline characteristics and comorbid risk factors for SPE and pleural infection were compared using Fisher’s exact tests for categorical variables, and the Mann-Whitney U-test for non-parametric continuous variables. The Kaplan–Meier (KM) method and Cox proportional hazard regression model were used for calculation of survival at 30-, 90-and 365-days following first positive pneumococcal microbiological test. Proportional hazard assumptions were tested by visual assessment of the KM survival curve, log(-log) plots and Schoenfeld residuals. Survival differences were analyzed using the log-rank test. Statistical analysis was performed using SPSS, version 28.0 (New York, IBM). Graphs were generated in GraphPad PRISM, version 9.0.

## RESULTS

2657 IPD episodes were identified, of which 2447 were respiratory infections: 1888 pneumonia cases, 459 SPE and 100 cases of pleural infection (Figure 1). 283/559 (51%) cases with parapneumonic effusion had *S. pneumoniae* confirmed on blood culture, and in 42 cases pneumococcus was isolated from pleural fluid. In total, 282/559 (50%) were male with a median age of 68y (IQR 50-78) (Table 1, Supplementary Data 2). Pre-existing cardiac and respiratory disease was common in patients with parapneumonic effusions. Patients with pleural infection were younger than those with SPE (median ages 55 vs 69y respectively, *P*<0.001), and were more likely to have history of alcohol misuse and/or intravenous drug usage (*P*<0.05) and less likely to develop acute renal failure (*P*<0.05). On presentation to hospital, neither clinical observations nor CURB65 score differed significantly between patients with SPE and pleural infection (*P* >0.05); in contrast, patients with pleural infection had both a significantly greater neutrophilia (*P*<0.01) and more elevated CRP levels (*P*<0.001) (Table 1, Supplementary Data 2 and 3).

![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/06/30/2022.03.16.22272461/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2022/06/30/2022.03.16.22272461/F1)

Figure 1: Study Cohort
Results from 3677 microbiology database occurrences of a positive blood or urine antigen test were identified. There were 2657 cases of pneumococcal infection in adults, including 559 patients with parapneumonic effusions.

View this table:
[Table 1:](http://medrxiv.org/content/early/2022/06/30/2022.03.16.22272461/T1)

Table 1: Clinical features of patients with pneumococcal parapneumonic effusions

Annual incidence of *S. pneumoniae* parapneumonic effusions increased throughout the study period (Figure 2A). There was a 33% and 34% increase in unplanned hospital admissions and microbiological testing between 2006 and 2018 (Supplementary Data 4, indicating relative increase in hospital workload was not equivalent to the increase in disease incidence. The age of patients admitted throughout the study did not show any apparent trend (Supplementary Data 5). In 38% cases serotype was available, of which overall 52% were attributable to a PCV13 serotype while only 8% were caused by a non-vaccine serotype. Over the study period, there was an absolute and proportional decrease in disease caused by PCV7 serotypes. All parapneumonic effusions caused by a PCV7 serotype after 2011 were SPE (serotypes 14 and 19F), with no pleural infections caused by a PCV7 serotype after 2011. PCV13-7 disease showed an initial rise, followed by a fall after PCV13 introduction with a gradual rise in disease over the last 5 study years (Figure 2B). Following the introduction of PCV13 in 2010, the only PCV13-7 serotypes that caused pneumococcal pleural infections were 1 and 3: 2 (17% of serotype known disease) and 3 (25%) pre-2010 pleural infection cases versus 9 (30%) and 7 (23%) post-2010 pleural infection cases due to serotype 1 and 3 respectively. Serotype 1 affected younger patients than serotype 3, but was associated with increased rates of renal failure (77% versus 43%, *P*=0.007), higher RAPID severity group (high RAPID severity group 36% versus 17%, *P*=0.024) and a trend towards higher loculation rates (23% versus 10%, *P*=0.205) than seen in patients with serotype 3 parapneumonic effusions (Table 2).

![Figure 2:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/06/30/2022.03.16.22272461/F2.medium.gif)

[Figure 2:](http://medrxiv.org/content/early/2022/06/30/2022.03.16.22272461/F2)

Figure 2: Vaccine group serotype trends in pneumococcal parapneumonic effusions in Bristol, UK 2006-2018
(A) Incidence of pneumococcal parapneumonic effusion (per 100,000 adults), calculated using adult population data from the Office of National Statistics (Supplementary Data 4).

(B) proportion of serotyped disease caused by vaccine serotype group as shown from 2006-

18. Dashed lines show the introduction of paediatric PCV7 and PCV13.

View this table:
[Table 2:](http://medrxiv.org/content/early/2022/06/30/2022.03.16.22272461/T2)

Table 2: Clinical features of patients with serotype 1 and 3 pneumococcal parapneumonic effusions

Overall, 19% patients with pneumococcal parapneumonic effusions died within 90-days of presentation (Table 1, Supplementary Table 6). Patients with pleural infections had higher survival rates than those with SPE at 30-, 90-and 365-days (*P*<0.01) (Figure 3A). Median survival was 468 days (340-590 days, 95% CI) in patients with pleural infection, vs 286 (274-335 days, 95% CI) in those with SPE. In total, 59/100 (59%) pleural infection patients had pus and these patients had improved 30-, 90-, and 365-day mortality compared to those without pus; in contrast, loculation was associated with reduced 30-, 90-and 365-day mortality (Table 4). Surgical management was associated with improved prognosis: no deaths occurred within 1-year of presentation compared to 24% mortality in patients with pleural infection who did not undergo surgery. Patients undergoing thoracic surgery were younger than those who did not (median age 45 years, IQR40-52 versus 66 years, IQR53-78).

![Figure 3:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/06/30/2022.03.16.22272461/F3.medium.gif)

[Figure 3:](http://medrxiv.org/content/early/2022/06/30/2022.03.16.22272461/F3)

Figure 3: 1-year survival in patients with pneumococcal parapneumonic effusions
(A) Kaplan-Meier survival curve and number at risk for patients with simple parapneumonic effusion (SPE) (red line) and pleural infection (blue line). (B) Kaplan-Meier survival curve and number at risk for patients with pneumococcal pleural infection for low (red line), medium (blue line) ad high (black line) RAPID score groups. The number of subjects at risk immediately before each time point is listed in a numbers-at-risk table.

The mortality rate among patients with pleural infection increased alongside RAPID score severity at 30-, 90-and 365-days (Figure 3B, Table 3), and a high RAPID score was associated with a median survival of 56 days (20-154 days, 95% CI). Proportional hazards regression analysis confirmed that more severe RAPID group was associated with increased 90-day (*P*=0.049, 95% CI 1.24-40.06) and 365-day mortality (*P*=0.034, 95% CI 1.09-51.2) (Table 4).

View this table:
[Table 3:](http://medrxiv.org/content/early/2022/06/30/2022.03.16.22272461/T3)

Table 3: Mortality among 100 Pneumococcal Pleural Infection cases with different clinical features and RAPID severity Scores

View this table:
[Table 4:](http://medrxiv.org/content/early/2022/06/30/2022.03.16.22272461/T4)

Table 4: Cox Regression Analysis for risk factors in patients with pleural infection

## DISCUSSION

This observational cohort study, with data from a 13-year period spanning PCV introduction into the UK childhood vaccination programme, shows an increasing incidence of adult pneumococcal parapneumonic effusions. An increasing incidence of pneumococcal disease has also been reported by other UK studies (9, 16, 20, 21), with Pick *et al* reporting incidence of pneumococcal pneumonia of 32.2 and 48.2 per 100,000 population in 2013 and 2018 respectively (9). Using previously published estimates that up to 20% of adults hospitalised with pneumococcal pneumonia develop a pleural effusion (10, 11), estimates of parapneumonic effusion incidence from that study would be 6.4 and 9.6 in 2013 and 2018, which are similar to the incidence rates of 5.0 and 9.8 observed in the same years in this study. Recent national epidemiological studies of pleural infection from North America also show significant increases in pleural infection rates both in children (22) and adults (23). Likewise, a Danish study from 1997-2001, showed steadily rising pleural infection rates in the elderly (24) and a UK study showed annual rises in adult pleural infections from 2008-17 (25), most marked in over 60-year-old individuals with a 194% increase over the decade. Both overall admissions and microbiological testing at the study hospitals increased progressively during our study period, but not as much as disease incidence, suggesting this did not solely account for the increasing incidence observed. Whilst the study period encompassed a time when the UK vaccination programme changed, there was also an expanding total and older adult population in Bath and Bristol. Furthermore, there may have been changes in patient or physician treatment preferences, including threshold for referral to secondary care, diagnostic testing and treatment which may have impacted the incidence of disease estimated throughout this study (26).

The introduction of PCV7 into the UK childhood vaccination programme in 2006 was followed by a decrease in adult pneumococcal pleural effusions attributable to PCV7 vaccine serotypes in this study. Notably, all parapneumonic effusions due to PCV7 serotypes after 2011 were SPE and due to serotypes 14 and 19F, with no cases of pleural infection. However, PCV13 introduction in 2010 did not result in such a marked indirect reduction in disease caused by the additional six serotypes in PCV13 due to the persistence of serotype 1 or 3 disease. This partially aligns with national serotype trends, showing reductions in both PCV7 serotype and serotype 1 adult IPD incidence (6), and both serotypes are prevalent in studies of pleural infection in children (27). In the UK, large reductions in vaccine-serotype adult IPD were offset by increases in non-PCV13 IPD (6, 16, 20), a trend also apparent in this patient cohort, with non-PCV13 disease increasing from 30% to 60% of known serotype disease. Pick *et al* showed an increase in non-PCV13 serotype pneumococcal pneumonia from 2014/15 onwards (9) as well as an overall increase in PCV13-7 serotype disease, in contrast to trends reported in this study. These are the first data on serotype trends in adult pneumococcal pleural disease since paediatric PCV introduction in the UK.

Serotype affects pneumococcal resistance to innate immunity, duration of nasopharyngeal colonisation, the number of episodes of invasive disease per colonisation event, morality and disease severity (28-30). The two PCV13-7 serotypes which continued to cause pneumococcal pleural infection following PCV13 introduction are notable serotypes as they have unusual polysaccharide capsules. Serotype 1 expresses a zwitterionic and structurally diverse polysaccharide capsule, which uniquely may act as a T-cell dependent antigen (31). This serotype rarely causes asymptomatic nasopharyngeal colonization but is a commonly isolated in IPD (28), and frequently causes invasive pneumonia (32). Studies suggests serotype 1 is more likely to be identified in young patients, and in some studies it is the most frequent cause of pneumococcal pleural infection, with increasing pleural infection incidence attributable to this serotype (11, 13). In contrast, the serotype 3 polysaccharide capsule is large, resulting in a highly mucoid appearance, and is one of a few capsules produced by synthase-mediated synthesis (33). Serotype 3 also causes considerable disease burden (11, 27) being the most common overall cause of pneumonia in the USA (34), is highly invasive (28) and is associated with increased mortality (29). Distinct lineages exist within serotype 3 clonal complex 180, and recent clade distributions shift has led to the emergence and expansion of clade II (35, 36), which now represents 50% serotype 3 IPD in the UK (37). We could not determine serotype 3 clade grouping in this analysis, but clade II emergence may, at least in part, explain serotype 3 disease persistence.

Overall, pre-existing medical conditions were commonly present amongst adults with pneumococcal parapneumonic effusions, although the median patient age was lower than that seen in other cohorts of parapneumonic effusions (12, 25). Uniquely, this cohort of parapneumonic effusion cases were all attributable to pneumococcal infection, which may cause the condition in younger patients than other pathogens (25, 38). Despite this, the burden of pre-existing medical comorbidity was equivalent: both SPE and pleural infection patients had significant cardiac (44%) and respiratory (43%) conditions predominating. A large systematic review found that 72% of patients with pleural infection had at least one significant comorbidity, with high levels of pre-existing cardiac (19%) and respiratory (20%) diseases (38). Excessive alcohol consumption was significantly more common among pleural infection cases, in line with other published cohort studies (14). Alcohol abuse may predispose to the development of pleural infection through its general immunosuppressive effect in addition to associated increases in risk of aspiration and delayed presentation to medical services (12).

As shown in the initial validation and subsequent cohort studies of the RAPID score (18, 19), a high score was strongly associated with the risk of mortality by 3-months. Study patients in the low-risk group had a 3% (95% C.I 0.7 to 15%) risk of 90-day mortality compared to 57% (95% C.I. 28% to 82% *P*<0.01), for those with a high risk score, while there was much less difference in survival between those in low and medium RAPID groups, as reported by others (19, 39). There was a positive association between pleural fluid purulence and survival: this relationship has been demonstrated in cohorts that were not restricted by causative organism, suggesting it is disease and not pathogen specific (18). Anecdotal report findings suggest effusions comprised of frank pus tend to be non-loculated and therefore more readily drained.

Interestingly, our data suggests that patients with pneumococcal pleural infection have improved survival up to one year compared to patients with pneumococcal SPE. It should be noted that up to 30% of effusions are known to have more than one aetiology (40), with many having a cardiac or renal component. It therefore can be difficult to determine the full aetiology of a pleural effusion, and pneumococcal SPEs may be often due to dual aetiology e.g. infection, causing atrial fibrillation and cardiac failure. In this cohort, pre-existing cardiac disease and bilateral effusions were more common in patients with SPE. Previous data suggests individuals with pneumonia and cardiac failure have higher mortality rates (41), and bilateral effusions are associated with worse outcomes (41, 42). Hence, whilst some effusions reflect more severe lung inflammation, others may reflect concomitant comorbidity in the host; either factor can account for worse outcome and may explain this finding in our cohort. Further, the high proportion of patients undergoing surgical intervention, which is associated with improved outcomes (43, 44), may have improved patient survival in the pleural infection patients.

This study identified patients with pneumococcal infection and parapneumonic effusions within a defined geographical area, covering a population of approximately one million adults, and encompassed 3 large hospitals with 100,000 unplanned adult admissions annually. One of these hospitals is the regional thoracic surgery centre, whilst another has a specialist pleural disease service, possibly increasing the accuracy of the clinical data presented here. We captured disease and serotype trends over 13 years, spanning PCV introduction. By linking with the UKHSA national reference laboratory we were able to report serotype where it was available. Importantly, the epidemiological data were supported with detailed clinical information for individual patients, including short- and long-term outcomes. However, this study also has limitations. This is a retrospective observational study; therefore, only information documented in clinical records could be included and patients were managed at the discretion of individual physicians. As a regional study, the findings here may not be representative of other populations; although, our serotype trends are comparable to other UK national and regional reports. We included patients who tested positive for pneumococcus using the BinaxNOW® urinary antigen test, which has a known sensitivity of 65% and prolonged positive test result after exposure to pneumococcus (45). Lastly, different methodologies were used to identify pneumococcal serotypes during the study period; whole genomic sequencing was only routinely used by UKHSA from October 2017, and therefore earlier isolates did not have this performed.

Overall, we found an increasing incidence of pneumococcal parapneumonic effusion in this UK population. The proportion of disease attributable to PCV7 serotypes fell after 2006, when the PCV7 vaccine was introduced into the UK childhood vaccination programme; importantly, no cases of PCV7 pleural infection occurred in adults after 2011. However, disease attributable serotypes 1 and 3 did not show decline following PCV13 vaccine rollout. Further research is needed to determine if *S. pneumoniae* serotype is predictive of mortality risk in adults with pneumococcal parapneumonic effusions.

## Supporting information

Supplementary Data [[supplements/272461_file05.docx]](pending:yes)

## Data Availability

The data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality rules. Therefore, individual participant data and a data dictionary is not available to other researchers.

## DATA SHARING

The data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality rules. Therefore, individual participant data and a data dictionary is not available to other researchers.

## ACKNOWLEDGEMENTS

The authors would like to acknowledge the research teams at The Royal United, North Bristol and University Hospitals of Bristol and Weston NHS Trusts.

## Footnotes

*   **Descriptor:** 9.31 Pleural Diseases/Mesothelioma

*   **Funding:** CH was funded by the National Institute for Health Research [NIHR Academic Clinical Fellowship (ACF-2015-25-002). DTA was funded by an NIHR Doctoral Research Fellowship (DRF-2018-11-ST2-065). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

*   **Declarations:** CH is Principal Investigator of the AvonCAP study which is an investigatorled University of Bristol study funded by Pfizer. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates Foundation. The other authors have no relevant conflicts of interest to declare.

*   the figures and discussion have been updated for clarity

*   Received March 16, 2022.
*   Revision received June 30, 2022.
*   Accepted June 30, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## REFERENCES

1.  1.UKHSA. Pneumococcal: The green book. 2020. p. 1–13.
    
    

2.  2.Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. New England Journal of Medicine 2003;348(18):1737–1746.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa022823&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12724479&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000182543500002&link_type=ISI) 

3.  3.Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clinical Infectious Diseases 2014;59(8):1066–1073.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciu524&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25034421&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

4.  4.Kelly MM, Coller RJ, Kohler JE, Zhao Q, Sklansky DJ, Shadman KA, Thurber A, Barreda CB, Edmonson MB. Trends in hospital treatment of empyema in children in the united states. The Journal of Pediatrics 2018;202:245–251.e241.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jpeds.2018.07.004&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

5.  5.Weinberger DM, Harboe ZB, Shapiro ED. Developing better pneumococcal vaccines for adults. JAMA Internal Medicine 2017;177(3):303–304.
    
    

6.  6.Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in england and wales, 2000-2013;17: A prospective national observational cohort study. The Lancet Infectious Diseases 2018;18(4):441–451.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(18)30052-5&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29395999&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

7.  7.Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in england and wales: An observational cohort study. Lancet Infect Dis 2011;11(10):760–768.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(11)70090-1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21621466&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000295768700021&link_type=ISI) 

8.  8.Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in england and wales 4 years after its introduction: An observational cohort study. Lancet Infect Dis 2015;15(5):535–543.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(15)70044-7&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25801458&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

9.  9.Pick H, Daniel P, Rodrigo C, Bewick T, Ashton D, Lawrence H, Baskaran V, Edwards-Pritchard RC, Sheppard C, Eletu SD, et al. Pneumococcal serotype trends, surveillance and risk factors in uk adult pneumonia, 2013–18. Thorax 2020;75(1):38.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToidGhvcmF4am5sIjtzOjU6InJlc2lkIjtzOjc6Ijc1LzEvMzgiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wNi8zMC8yMDIyLjAzLjE2LjIyMjcyNDYxLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

10. 10.Vallés X, Marcos A, Pinart M, Piñer R, Marco F, Mensa JM, Torres A. Hospitalized community-acquired pneumonia due to streptococcus pneumoniae: Has resistance to antibiotics decreased? Chest 2006;130(3):800–806.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1378/chest.130.3.800&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=16963678&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000240585600029&link_type=ISI) 

11. 11.Cillóniz C, Ewig S, Polverino E, Muñoz-Almagro C, Marco F, Gabarrús A, Menéndez R, Mensa J, Torres A. Pulmonary complications of pneumococcal community-acquired pneumonia: Incidence, predictors, and outcomes. Clinical Microbiology and Infection 2012;18(11):1134–1142.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1469-0691.2011.03692.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22044658&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

12. 12.Chalmers JD, Singanayagam A, Murray MP, Scally C, Fawzi A, Hill AT. Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia. Thorax 2009;64(7):592.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToidGhvcmF4am5sIjtzOjU6InJlc2lkIjtzOjg6IjY0LzcvNTkyIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDYvMzAvMjAyMi4wMy4xNi4yMjI3MjQ2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

13. 13.Wagenvoort GHJ, Sanders EAM, Vlaminckx BJ, Elberse KE, de Melker HE, van der Ende A, Knol MJ. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2–6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the netherlands. Vaccine 2016;34(8):1077–1085.
    
    

14. 14.Falguera M, Carratalà J, Bielsa S, García-Vidal C, Ruiz-González A, Chica I, Gudiol F, Porcel JM. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. European Respiratory Journal 2011;38(5):1173.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiZXJqIjtzOjU6InJlc2lkIjtzOjk6IjM4LzUvMTE3MyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIyLzA2LzMwLzIwMjIuMDMuMTYuMjIyNzI0NjEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

15. 15.Hyams C, Amin-Chowdhury Z, Fry NK, North P, Finn A, Judge A, Ladhani SN, Williams OM. Streptococcus pneumoniae septic arthritis in adults in bristol and bath, united kingdom, 2006–2018: A 13-year retrospective observational cohort study. Emerging Microbes & Infections 2021;10(1):1369–1377.
    
    

16. 16.Amin-Chowdhury Z, Collins S, Sheppard C, Litt D, Fry NK, Andrews N, Ladhani SN. Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in england: A prospective observational cohort study, 2014–2018. Clinical Infectious Diseases 2020.
    
    

17. 17.Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 2003;58(5):377.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6OToidGhvcmF4am5sIjtzOjU6InJlc2lkIjtzOjg6IjU4LzUvMzc3IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDYvMzAvMjAyMi4wMy4xNi4yMjI3MjQ2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

18. 18.Rahman NM, Kahan BC, Miller RF, Gleeson FV, Nunn AJ, Maskell NA. A clinical score (rapid) to identify those at risk for poor outcome at presentation in patients with pleural infection. Chest 2014;145(4):848–855.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1378/chest.13-1558&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24264558&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

19. 19.Corcoran JP, Psallidas I, Gerry S, Piccolo F, Koegelenberg CF, Saba T, Daneshvar C, Fairbairn I, Heinink R, West A, et al. Prospective validation of the rapid clinical risk prediction score in adult patients with pleural infection: The pilot study. European Respiratory Journal 2020:2000130.
    
    

20. 20.Houseman C, Hughes GJ, Chapman KE, Wilson D, Gorton R. Increased invasive pneumococcal disease, north east england, uk. Emerging infectious diseases 2017;23(1):122–126.
    
    

21. 21.Abram SGF, Alvand A, Judge A, Beard DJ, Price AJ. Mortality and adverse joint outcomes following septic arthritis of the native knee: A longitudinal cohort study of patients receiving arthroscopic washout. The Lancet Infectious Diseases 2020;20(3):341–349.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(19)30419-0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

22. 22.Finley C, Clifton J, Fitzgerald JM, Yee J. Empyema: An increasing concern in canada. Canadian respiratory journal 2008;15(2):85–89.
    
    

23. 23.Mummadi SR, Stoller JK, Lopez R, Kailasam K, Gillespie CT, Hahn PY. Epidemiology of adult pleural disease in the united states. Chest 2021;160(4):1534–1551.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

24. 24.Søgaard M, Nielsen RB, Nørgaard M, Kornum JB, Schønheyder HC, Thomsen RW. Incidence, length of stay, and prognosis of hospitalized patients with pleural empyema: A 15-year danish nationwide cohort study. Chest 2014;145(1):189–192.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

25. 25.Arnold DT, Hamilton FW, Morris TT, Suri T, Morley A, Frost V, Vipond IB, Medford AR, Payne RA, Muir P, et al. Epidemiology of pleural empyema in english hospitals and the impact of influenza. European Respiratory Journal 2020:2003546.
    
    

26. 26.Maguire D, Dunn P, McKenna H. How hospital activity in the nhs in england has changed over time. 2016.
    
    

27. 27.Fletcher MA, Schmitt HJ, Syrochkina M, Sylvester G. Pneumococcal empyema and complicated pneumonias: Global trends in incidence, prevalence, and serotype epidemiology. European Journal of Clinical Microbiology & Infectious Diseases 2014;33(6):879–910.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10096-014-2062-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24563274&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

28. 28.Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. The Journal of Infectious Diseases 2003;187(9):1424–1432.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1086/374624&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12717624&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000182273700010&link_type=ISI) 

29. 29.Weinberger DM, Harboe ZB, Sanders EAM, Ndiritu M, Klugman KP, Rückinger S, Dagan R, Adegbola R, Cutts F, Johnson HL, et al. Association of serotype with risk of death due to pneumococcal pneumonia: A meta-analysis. Clinical Infectious Diseases 2010;51(6):692–699.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1086/655828&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20715907&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000281143400008&link_type=ISI) 

30. 30.Hyams C, Yuste J, Bax K, Camberlein E, Weiser JN, Brown JS. Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype. Infect Immun 2010;78(2):716–725.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiaWFpIjtzOjU6InJlc2lkIjtzOjg6Ijc4LzIvNzE2IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDYvMzAvMjAyMi4wMy4xNi4yMjI3MjQ2MS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

31. 31.Kaushal N, Kumari S, Jhelum H, Sehgal D. In vitro and in vivo characterization of the interaction, proinflammatory, immunomodulatory and antigenic properties of capsular polysaccharide from streptococcus pneumoniae serotype 1. International Journal of Biological Macromolecules 2020;143:521–532.
    
    

32. 32.Bergman K, Härnqvist T, Backhaus E, Trollfors B, Dahl MS, Kolberg H, Ockborn G, Andersson R, Karlsson J, Mellgren Å, et al. Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in southwest sweden. BMC Infectious Diseases 2021;21(1):756.
    
    

33. 33.Luck JN, Tettelin H, Orihuela CJ. Sugar-coated killer: Serotype 3 pneumococcal disease. Frontiers in Cellular and Infection Microbiology 2020;10.
    
    

34. 34.Pande A, Nasir S, Rueda AM, Matejowsky R, Ramos J, Doshi S, Kulkarni P, Musher DM. The incidence of necrotizing changes in adults with pneumococcal pneumonia. Clinical Infectious Diseases 2012;54(1):10–16.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/cir749&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22042878&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

35. 35.Azarian T, Mitchell PK, Georgieva M, Thompson CM, Ghouila A, Pollard AJ, von Gottberg A, du Plessis M, Antonio M, Kwambana-Adams BA, et al. Global emergence and population dynamics of divergent serotype 3 cc180 pneumococci. PLOS Pathogens 2018;14(11):e1007438.
    
    

36. 36.Croucher NJ, Mitchell AM, Gould KA, Inverarity D, Barquist L, Feltwell T, Fookes MC, Harris SR, Dordel J, Salter SJ, et al. Dominant role of nucleotide substitution in the diversification of serotype 3 pneumococci over decades and during a single infection. PLOS Genetics 2013;9(10):e1003868.
    
    

37. 37.Groves N, Sheppard CL, Litt D, Rose S, Silva A, Njoku N, Rodrigues S, Amin-Chowdhury Z, Andrews N, Ladhani S, et al. Evolution of streptococcus pneumoniae serotype 3 in england and wales: A major vaccine evader. Genes 2019;10(11).
    
    

38. 38.Cargill TN, Hassan M, Corcoran JP, Harriss E, Asciak R, Mercer RM, McCracken DJ, Bedawi EO, Rahman NM. A systematic review of comorbidities and outcomes of adult patients with pleural infection. European Respiratory Journal 2019:1900541.
    
    

39. 39.White HD, Henry C, Stock EM, Arroliga AC, Ghamande S. Predicting long-term outcomes in pleural infections. Rapid score for risk stratification. Annals of the American Thoracic Society 2015;12(9):1310–1316.
    
    

40. 40.Bintcliffe OJ, Hooper CE, Rider IJ, Finn RS, Morley AJ, Zahan-Evans N, Harvey JE, Skyrme-Jones AP, Maskell NA. Unilateral pleural effusions with more than one apparent etiology. A prospective observational study. Annals of the American Thoracic Society 2016;13(7):1050–1056.
    
    

41. 41.Hasley PB, Albaum MN, Li YH, Fuhrman CR, Britton CA, Marrie TJ, Singer DE, Coley CM, Kapoor WN, Fine MJ. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia? Arch Intern Med 1996;156(19):2206–2212.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/archinte.1996.00440180068008&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=8885819&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1996VN93900007&link_type=ISI) 

42. 42.Dean NC, Jones BE, Jones JP, Ferraro JP, Post HB, Aronsky D, Vines CG, Allen TL, Haug PJ. Impact of an electronic clinical decision support tool for emergency department patients with pneumonia. Ann Emerg Med 2015;66(5):511–520.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.annemergmed.2015.02.003&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25725592&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 

43. 43.Federici S, Bédat B, Hayau J, Gonzalez M, Triponez F, Krueger T, Karenovics W, Perentes JY. Outcome of parapneumonic empyema managed surgically or by fibrinolysis: A multicenter study. Journal of Thoracic Disease 2021;13(11):6381–6389.
    
    

44. 44.Wait MA, Sharma S, Hohn J, Dal Nogare A. A randomized trial of empyema therapy. Chest 1997;111(6):1548–1551.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1378/chest.111.6.1548&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=9187172&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F06%2F30%2F2022.03.16.22272461.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1997XC90200019&link_type=ISI) 

45. 45.Hyams C, Williams OM, Williams P. Urinary antigen testing for pneumococcal pneumonia: Is there evidence to make its use uncommon in clinical practice? ERJ Open Research 2020;6(1):00223–02019.